Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (241-250 of 272) with videos related to

Pageof 28
Sort By:
RMD Open|March 25, 2022
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trialsIain B McInnes, Andrew J K Ostor, Philip J Mease, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trialDésirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Pharmacology & Therapeutics|June 25, 2021
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyFrank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis Research & Therapy|May 16, 2023
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritisJuergen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Arthritis Research & Therapy|September 5, 2021
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENTJürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Lancet (London, England)|December 10, 2019
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trialAtul Deodhar, Désirée van der Heijde, Lianne S Gensler, et al.
Pageof 28

Showing results (241-250 of 272) with videos related to

Sort By:
Pageof 28
RMD Open|March 25, 2022
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trialsIain B McInnes, Andrew J K Ostor, Philip J Mease, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trialDésirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Pharmacology & Therapeutics|June 25, 2021
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyFrank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis Research & Therapy|May 16, 2023
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritisJuergen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Arthritis Research & Therapy|September 5, 2021
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENTJürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, et al.
Rheumatology (Oxford, England)|May 13, 2017
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpADésirée van der Heijde, Maxime Dougados, Robert Landewé, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Lancet (London, England)|December 10, 2019
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trialAtul Deodhar, Désirée van der Heijde, Lianne S Gensler, et al.
Pageof 28